CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
CALIWAY BIOPHARMACEUTICALS CO L - Asset Resilience Ratio
CALIWAY BIOPHARMACEUTICALS CO L (6919) has an Asset Resilience Ratio of 37.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how CALIWAY BIOPHARMACEUTICALS CO L's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CALIWAY BIOPHARMACEUTICALS CO L's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$3.51 Billion | 37.17% |
| Total Liquid Assets | NT$3.51 Billion | 37.17% |
Asset Resilience Insights
- Very High Liquidity: CALIWAY BIOPHARMACEUTICALS CO L maintains exceptional liquid asset reserves at 37.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CALIWAY BIOPHARMACEUTICALS CO L Industry Peers by Asset Resilience Ratio
Compare CALIWAY BIOPHARMACEUTICALS CO L's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for CALIWAY BIOPHARMACEUTICALS CO L (2022–2024)
The table below shows the annual Asset Resilience Ratio data for CALIWAY BIOPHARMACEUTICALS CO L.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.32% | NT$2.77 Billion | NT$9.77 Billion | +20.76pp |
| 2023-12-31 | 7.56% | NT$289.40 Million | NT$3.83 Billion | -29.43pp |
| 2022-12-31 | 36.99% | NT$456.18 Million | NT$1.23 Billion | -- |